

# Behavioral Health eMeasures Depression Phase II Meeting 1 Technical Expert Panel • July 16, 2012



*Health in the 21<sup>st</sup> Century*

**MITRE**

# Agenda

- **Introduction (5 minutes)**
  - Welcome and Roll Call
  - Review project schedule
- **Goals, Outcomes, and Context**
  - **Project Goals and Outcomes (5 minutes)**
    - Review work to date
- **Today's Domain Discussion**
  - **Depression (60 minutes)**
    - Review new goal and task
    - Review of MU and Measure “Life Cycle”
    - Discussion of Trended measures
    - Discussion Questions
    - Homework
- **Next Steps and Questions (5 minutes)**



# Roll Call

# Core Team

## ■ SAMHSA

- Westley Clark, MD
- Maureen Boyle, PhD (TEP Co-lead)
- Ken Salyards
- Bob Stephenson

## ■ ONC

- Jesse James, MD
- Kevin Larsen, MD
- Lauren Richie (TEP Co-lead)
- Anca Tabakova
- Kate Tipping

## ■ CMS

- Carrie Feher

## ■ MITRE

- Beth Halley
- Nicole Kemper
- Saul Kravitz
- Maggie Lohnes
- Denise Sun
- Jocelyn Tafalla

# Technical Expert Panel- Community

Gavin	Bart	University of Minnesota- Hennepin County Medical Center
Rhonda	Beale	Chief Medical Officer @ OptumHealth Behavioral Solutions
Lyndra	Bills	Associate Medical Director for the Northeast Pennsylvania
Gregory	Brown	UPenn
Kate	Comtois	Harborview Medical Center
Geri	Dawson	Autism Speaks
Vincent	Felitte	Kaiser Permanente
Deborah	Garnick	Brandeis U Heller School
Frank	Ghinassi	UPMC
Eric	Goplerud	NORC
Rob	Gore-Langton	EMMES
Constance	Horgan	Brandeis U Heller School
Anna Mabel	Jones	Oxford House, Inc.
Rachel	Kimerling	Veterans Administration

**(Continued)**

# Technical Expert Panel - Community (Cont.)

Alex	Krist	Community Physician
Robert	Linblad	EMMES
Cathy	Lord	Institute for Brain Development, NY-Presbyterian Hosp
A Thomas	McLellan *	Treatment Research Institute
LaVerne	Miller	Policy Research Associates, Delmar, New York
Daniel	Mullin	UMass MHC
Keris	Myrick	Project Return Peer Support Network
Charlie	Reznikoff	University of Minnesota- Hennepin County Medical Center
Lucy	Savitz	Intermountain Healthcare
Robert	Schwartz	Friends Research Institute
Cheryl	Sharp	National Council for Community Behavioral Healthcare
Morton	Silverman	EDC
Piper	Svensson-Ranallo	University of Minnesota Institute for Health Informatics
Thomas	Swales	MetroHealth System/ Case Western Reserve University
Amy	Wetherby	Florida State University
Charles	Willis	Statewide Peer Wellness Initiative/GA Mental Health Consumer Network

(\* ad hoc)

# Subgroup Members – Federal Staff

ALCOHOL (3)		
Last Name	First Name	Agency
Boyle	Maureen	SAMHSA
Corbridge	Ian	HRSA
<b>Cotter</b>	<b>Frances</b>	<b>SAMHSA</b>
Dowling	Gaya	NIH/NIDA
Faden	Vivian	NIH/NIAAA
Forman	Reed	SAMHSA
Harris	Alex	VA
Lide	BJ	NIST
Lowman	Cheryl	NIH
McKnight-Eily	Lela	CDC
Tai	Betty	NIH/NIDA

AUTISM (2)		
Last Name	First Name	Agency
Blum	Alex	NIH
<b>Boyle</b>	<b>Maureen</b>	<b>SAMHSA</b>
Gilotty	Lisa	NIH
Kau	Alice	NIH/NICHD
Kavanagh	Laura	HRSA
Smith	Camille	CDC/ONDIEH/NCBDDD
Rice	Catherine	CDC/ONDIEH/NCBDDD
Wolf	Rebecca	CDC/ONDIEH/NCBDDD

DEPRESSION (6)		
Last Name	First Name	Agency
Alemu	Girma	HRSA
Azrin	Susan	NIH/NIMH
Boyle	Maureen	SAMHSA
Cotter	Fran	SAMHSA
Feher	Carrie	CMS
Harris	Yael	HRSA
LeFauve	Charlene	SAMHSA
<b>Ross</b>	<b>Alex</b>	<b>HRSA</b>

SUBSTANCE ABUSE (2)		
Last Name	First Name	Agency
Boyle	Maureen	SAMHSA
Dowling	Gaya	NIH/NIDA
<b>Ghitza</b>	<b>Udi</b>	<b>NIH/NIDA</b>
Lee	Jinhee	SAMHSA
Reuter	Nick	SAMHSA
Sivilli	June	ONDCP
Tai	Betty	NIH/NIDA

SUICIDE (2)		
Last Name	First Name	Agency
Boyle	Maureen	SAMHSA
Crosby	Alex	CDC
<b>Grenier</b>	<b>Denise</b>	<b>IHS</b>
Lysell	Katy	VA
McKeon	Richard	SAMHSA
Mullen	Mariquita	HRSA
Weglicki	Linda	NIH/NINR

TRAUMA (0)		
Last Name	First Name	Agency
Boyle	Maureen	SAMHSA
Cotton	Beverly	IHS
DeVoursney	David	SAMHSA
Harvell	Jennie	ASPE
Herne	Mose	IHS
Huang	Larke	SAMHSA
Ross	Alex	HRSA
<b>Salyards</b>	<b>Ken</b>	<b>SAMHSA</b>
Young	Elise	HRSA

**Bold = Lead**  
**(#) = High Priority Measures**

# TEP PHASE II MEETING SCHEDULE and TOPICS

TEP Meeting Number	TEP PHASE II	
15	7/16 3-4:30pm Eastern	Depression – Week 1
16	7/23 3-4:30pm Eastern	Drug Use/PCM – Week 1
17	7/30 3-4:30pm Eastern	Depression – Week 2
18	8/6 3-4:30pm Eastern	Drug Use/PCM – Week 2
<b>NEW</b>	<b>8/9 All day event</b>	<b>In-Person and Webinar</b>
19	8/13 3-4:30pm Eastern	Depression – Week 3 *if needed
20	8/20 3-4:30pm Eastern	Drug Use/PCM – Week 3 *if needed
21	8/27 3-4:30pm Eastern	Depression – Week 4 *if needed
22	9/3 3-4:30pm Eastern	Drug Use/PCM – Week 4 *if needed
23	9/10 3-4:30pm Eastern	Depression – Week 5 *if needed
24	9/17 3-4:30pm Eastern	Drug Use/PCM – Week 5 *if needed





# Goals and Outcomes

# Project Goal

**Develop a portfolio of behavioral health (BH) clinical quality measures (CQMs) suitable for inclusion in the EHR incentive program for Meaningful Use (MU) of Health Information Technology (IT)**



# Project Phase 2 – Outcomes

## TEP Phase I

- **Broad review of 6 domain areas with report of findings**
  - Perform Environmental Scan for non-NQF-endorsed measures  
Perform Clinical Literature Search for available evidence  
**(Meeting 1)**
  - TEP Review of Environmental Scan results **(Meeting 2 and 3)**
  - Measure Development Recommendations Report **(Meeting 3 and post-meetings)**

## TEP Phase II

- **Research Drug Use/ Prescription Drug Misuse (DU/PDM) Clinical Evidence**  
**(Meeting 4 and beyond)**
  - Document clinical evidence to support NQF-endorsement of effective DU/PDM care approaches
  - Document clinical evidence to support NQF-endorsement of effective SBIRT DU/PDM care approach
  - Fund clinical research of patient-entered SISQ

- **Support development of a trended Depression Outcome Clinical Quality Measure**  
**(Meeting 4 and beyond)**


# Technical Expert Panel (TEP) Schedule

MITRE

TEP

Subcontractor:  
Literature Search

Subcontractor:  
R. Saitz, MD



# Summary of Work To Date

DOMAIN	MEANINGFUL USE MEASURES		ENDORSED MEASURES (PROJECT PHASE 1 - Federal Subgroup)		NON-ENDORSED MEASURES ( TEP PHASE 1)		CLINICAL LITERATURE REVIEW ( TEP PHASE 1)	
	Measures from Stage 1	Measures in NPRM for Stage 2	Activity: Scan Focus	Results	Planned Activity	Anticipated Results	Planned Activity	Results
Depression	1 measure	11 measures	NQF Library	4 Measures Recommended (2 not included in MU Stage 2 NPRM)	AHRQ Library	4 Measures defined as "maybe" 6 Measures defined as "yes"	Deep Lit Search TEP Review	197 Literature results included in matrix covering 6 broad areas




# Today's Domain Discussions

Depression

# Review of TEP Domain success metrics

## ■ Depression



# Phase II TEP Task Overview

## ■ Task 1- TEP Phase II Orientation

- Brief review work to date
- Describe Phase II goal
  - Recommendations on the development of a trended outcome measure for depression
- Trended measure definition and construct
- Discussion
  - Discuss audience for the trended measure (EP vs. EH, PC vs. other specialty) and the usability/feasibility of this type of measure

## ■ Task 2 – Research and Deliberation

- Review research for trended PHQ-9 scores
- Overview of available measures for trending scores in PHQ-9
- Measure justification research against environmental scan results
- Evaluate available measures (e.g. MN Community Measurement measures); determine support in literature/research that can be used to create a new measure
- Determine questions for additional research or for review with measure developers

## ■ Task 3 – Final Recommendation


- Finalize recommendations on available measures OR recommendations on available research to support development of a trended measure





# Meaningful Use and the Measure “Life Cycle”

# Measure Development Process



MITRE depiction of combined CMS Blueprint v8 and NQF processes  
\* Developing industry standard




# Trended Measures

# Measure Types

- **ACCESS:** Attainment of timely and appropriate healthcare
- **COMPOSITE:** Combination of two+ individual measures into single measure with single score result
- **EFFICIENCY:** Cost of care associated with a specified level of quality of care
- **OUTCOME:** Achieving a particular state of health
  - *Trended: Tracking Outcome  $\Delta$  over time*
- **PATIENT EXPERIENCE:** Patient's observations of and participation in healthcare
- **PROCESS:** Clinical process which leads to a certain outcome
- **RESOURCE USE:** Broadly applicable health services counts (e.g. time, dollars) applied to patient event
- **STRUCTURAL:** Organization or clinician capacity to provide healthcare

# Meaningful Use: Meeting the Needs of Today and Tomorrow





# Measure Type Examples

# MU Stage 1 - Final Rule Measures – Core Set

Measure Number	Title and Description	Domain
	NONE	

# MU Stage 1 - Final Rule Measures – Menu Set

Measure Number	Title and Description	Domain
0105	Patients more than 18 years old who were diagnosed with a new episode of major depression and treated with antidepressant medication, and who remain on antidepressant medication treatment	Miscellaneous

# MU Stage 2 NPRM Proposed BH Measures

Measure Number	Title and Description	Domain
NQF 0004	Title: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	Clinical Process/ Effectiveness
NQF 0028	Title: Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment, b. Tobacco Cessation Intervention	Population/ Public Health
NQF 0103	Title: Major Depressive Disorder (MDD): Diagnostic Evaluation	Clinical Process/ Effectiveness
NQF 0104	Title: Major Depressive Disorder (MDD): Suicide Risk Assessment	Clinical Process/ Effectiveness
NQF 0105	Title: Anti-depressant Medication Management: (a) Effective Acute Phase Treatment, (b) Effective Continuation Phase Treatment	Clinical Process/ Effectiveness
NQF 0106	Title: Diagnosis of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents	Care Coordination
NQF 0107	Title: Management of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents	Clinical Process/ Effectiveness
NQF 0108	Title: ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication	Clinical Process/ Effectiveness
NQF 0110	Title: Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use	Clinical Process/ Effectiveness
NQF 0112	Title: Bipolar Disorder: Monitoring change in level-of-functioning	Clinical Process/ Effectiveness

**(Continued)**



# MU Stage 2 NPRM Proposed BH Measures (cont.)

Measure Number	Title and Description	Domain
NQF 0710	Title: Depression Remission at Twelve Months	Clinical Process/ Effectiveness
NQF 0711	Title: Depression Remission at Six Months	Clinical Process/ Effectiveness
NQF 0712	Title: Depression Utilization of the PHQ-9 Tool	Clinical Process/ Effectiveness
NQF 1365	Title: Child and Adolescent Major Depressive Disorder: Suicide Risk Assessment	Patient Safety
NQF 1401	Title: Maternal depression Screening	Population/ Public Health
TBD	Title: Depression screening and follow-up assessment using patient self-reported process	Patient and Family Engagement
TBD	Title: Closing the referral loop: receipt of specialist report	Care Coordination
NQF 0024	Title: Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents Description	Population/ Public Health
NQF 0421	Title: Adult Weight Screening and Follow-Up Description	Population/Public Health

# Prioritized NQF Endorsed Measures for eSpecification (not included in MU Stage 2 NPRM)

NQF Number	Measure Concept	Measure Title	Sub-group	Sub-Group Priority	Setting
580	Bipolar antimanic agent	Bipolar antimanic agent	Depression	2	EP
418	Depression Screening (PHQ-2 and PHQ-9) for primary care > age 13	Depression Screening (PHQ-2 and PHQ-9) for primary care > age 13	Depression	1	EP



# Discussion

Trended Measure for Depression

# Discussion Questions for Today's TEP

- **What questions do the TEP members have about creating a trended measure?**
  - Preliminary planning for detailed discussion with NQF
- **What is the target audience for this trended measure? Is there more than one target audience?**
  - EP and/or EH
  - PC vs. specialty care
- **What concerns might there be with usability/feasibility for this type of measure in an EHR environment?**
- **Is the change in PHQ-9 score the key variable for tracking in a trended measure?**
  - PROs: Significant research (see Matrix) and Potential existing measures (MN Community Health)
  - CONs: Very specific to one screener
  - Other concerns?

# Preparation for Next Discussion

## ■ TEP members

- Provide additional questions for review at next session with trended measure expert
- Review updated literature matrix prior to next meeting
  - Focused on validating trendable outcome measures
    - Consider strength of research on trending of the PHQ-9
- Provide additional requests for research/literature scans by 7/25

## ■ MITRE Team

- Review existing measures and identify research supporting these measures
- Develop matrix to ensure research is represented in literature scan results



# Next Steps/Questions

# Next Steps and Questions

- **Weekly Workshops**
  - Wednesdays at 3pm-4pm
- **Next TEP Meeting (Topic: Drug Use/Prescription Drug Misuse – Phase II Meeting 1):**
  - Monday, 7/23, 3-4:30pm Eastern (possible holiday schedule change)
- **Questions?**